★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Vertex is a U.S. biotechnology company focused on specialty medicines. In Q1 2026, CFTR modulators still generated about 97.6% of product revenue, led by TRIKAFTA/KAFTRIO and ALYFTREK. The CF moat rests on a deep Orange Book patent estate, long basic patent horizons, reimbursement access, and specialist-centered prescribing. CASGEVY adds a gene-editing franchise in sickle cell disease and transfusion-dependent beta thalassemia, supported by BLA exclusivity and treatment-center execution, but uptake remains operationally complex. JOURNAVX gives Vertex a first-in-class non-opioid acute-pain launch, though analgesics are highly competitive and payer-sensitive.
Primary segment
Cystic Fibrosis CFTR Modulators
Market structure
Quasi-Monopoly
Market share
72%-75% (reported)
HHI: —
Coverage
3 segments · 5 tags
Updated 2026-06-02
Segments
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
Revenue
97.6%
Structure
Quasi-Monopoly
Pricing
strong
Share
72%-75% (reported)
Peers
Hemoglobinopathies Gene Therapy (CASGEVY)
Gene-editing / gene therapy for sickle cell disease and transfusion-dependent beta thalassemia
Revenue
1.4%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Acute Pain (JOURNAVX)
Moderate-to-severe acute pain pharmacotherapy (non-opioid analgesics)
Revenue
1%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
Revenue share reflects Q1 2026 10-Q product revenue: total CF product revenue of $2.915B out of $2.987B total product revenue. Vertex estimates its CF medicines are used by nearly three quarters of about 97,000 people with CF in the U.S., Europe, Australia and Canada, and that about 112,000 people with CF live in all target markets.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Large Orange Book-listed patent estate plus regulatory exclusivity supports long-lived protection for CFTR modulators (including TRIKAFTA/KAFTRIO and ALYFTREK).
Erosion risks
- Patent challenges / invalidation
- Post-expiry generic entry after late-2030s
- Breakthrough non-modulator modalities (gene therapy, mRNA) reducing modulator demand
Leading indicators
- Orange Book litigation / Paragraph IV filings
- Competitor CF genetic therapy clinical milestones
- Net realized pricing trend and payer restriction rates
Counterarguments
- High pricing makes CF payers highly motivated to support cheaper alternatives when available
- A truly curative CF genetic therapy could bypass CFTR modulators entirely
Government Contracting Relationships
Legal
Government Contracting Relationships
Strength
Durability
Confidence
Evidence
Multi-year national reimbursement arrangements and new 2026 ALYFTREK access wins reduce near-term access friction and can entrench incumbent therapies for chronic diseases.
Erosion risks
- Policy-driven price cuts in single-payer systems
- Re-tendering or renegotiation of national reimbursement terms
Leading indicators
- Public payer re-opener clauses / renegotiation announcements
- HTA outcomes for future CF competitors
Counterarguments
- National payers can renegotiate aggressively if/when credible alternatives arrive
- Reimbursement agreements are not exclusive; competitors can still win access
Switching Costs General
Demand
Switching Costs General
Strength
Durability
Confidence
Evidence
Chronic, specialty-disease prescribing concentrated in CF centers plus strong clinical outcomes create inertia; patients/clinicians are cautious about switching stable regimens.
Erosion risks
- Superior efficacy/safety from a new entrant making switching rational
- Payer-mandated switching to lower-cost options
Leading indicators
- Share of CF population on Vertex medicines
- Real-world evidence comparing next-gen regimens (e.g., ALYFTREK vs TRIKAFTA)
- Payer prior-authorization tightening
Counterarguments
- If a competitor demonstrates clearly superior outcomes, specialists can switch quickly
- Payers can force switching despite clinician/patient preferences
Benchmark Pricing Power
Financial
Benchmark Pricing Power
Strength
Durability
Confidence
Evidence
Rare-disease, high-value therapies with limited alternatives have historically supported price realization and periodic net price uplift, tempered by payer rebates.
Erosion risks
- Drug-pricing reform expanding to orphan drugs
- Step-edits / tighter utilization management
Leading indicators
- Net realized price per patient trend
- Gross-to-net percentage trend
- Government pricing policy changes
Counterarguments
- Price is constrained by payer rebates and public scrutiny
- Future competition could reset the pricing benchmark
Hemoglobinopathies Gene Therapy (CASGEVY)
Gene-editing / gene therapy for sickle cell disease and transfusion-dependent beta thalassemia
Revenue share reflects Q1 2026 10-Q product revenue: CASGEVY product revenue of $42.9M out of $2.987B total product revenue. Vertex remains commercialization lead under the CRISPR collaboration, with economics shared with CRISPR Therapeutics.
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
BLA pathway provides multi-year regulatory exclusivity; CASGEVY also benefits from orphan-style barriers (specialized centers, conditioning regimens).
Erosion risks
- Competing gene therapies / gene editing with better safety, simpler conditioning, or lower total cost
- Regulatory changes for cell/gene therapy manufacturing and patient support
Leading indicators
- Number of authorized treatment centers activated
- Patient cell collection / infusion run-rate
- Competitor approvals and label expansions
Counterarguments
- First-to-market advantage may be limited if competitors scale faster or offer easier logistics
- Long-term safety data are still accruing, potentially constraining uptake
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
A global network of authorized transplant centers and growing patient starts can increase capacity, reduce friction, and create operational switching costs for hospitals.
Erosion risks
- Centers multi-home (offer multiple therapies), reducing exclusivity
- Manufacturing or scheduling bottlenecks shifting centers to competitors
Leading indicators
- Center activation growth and geographic coverage
- Cycle times from cell collection to infusion
- Manufacturing slot utilization
Counterarguments
- Large academic centers can onboard competing therapies quickly
- Payers may direct patients to lower-cost competitor offerings regardless of center relationships
Capacity Moat
Supply
Capacity Moat
Strength
Durability
Confidence
Evidence
Cell/gene therapy manufacturing scale-up, QA, and supply coordination can be a bottleneck; early commercial-scale capacity can constrain rivals.
Erosion risks
- CDMO capacity expansion reducing supply bottlenecks
- Process improvements by competitors lowering COGS and scaling faster
Leading indicators
- Manufacturing success rate / batch failure disclosures
- Reported infusion capacity and backlog
Counterarguments
- Competitors can contract with major CDMOs and scale quickly if demand is proven
- Manufacturing constraints may cap Vertex growth as much as rivals
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent and know-how protection on gene-editing constructs and manufacturing processes can raise freedom-to-operate barriers, but CRISPR IP is complex and litigated.
Erosion risks
- IP litigation outcomes weakening protection
- Alternative editing modalities (base/prime editing) avoiding key patents
Leading indicators
- Patent litigation filings/settlements related to CRISPR editing
- Competitor platform shifts to non-infringing approaches
Counterarguments
- CRISPR IP landscape is fragmented, making durable exclusion difficult
- Clinical execution and logistics may matter more than patents for near-term share
Acute Pain (JOURNAVX)
Moderate-to-severe acute pain pharmacotherapy (non-opioid analgesics)
Revenue share reflects Q1 2026 10-Q product revenue: JOURNAVX product revenue of $29.0M out of $2.987B total product revenue. Q1 2026 filing disclosed Medicaid coverage in 22 states and about 240M individuals with access, but broad analgesics competition remains intense.
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
First-in-class FDA approval creates a time lead versus follow-on NaV1.8 inhibitors and enables branded launch into a large acute pain market.
Erosion risks
- Rapid follow-on competition (me-too NaV1.8 inhibitors)
- Payer restrictions and preference for low-cost generics/opioids
Leading indicators
- Formulary wins and utilization-management intensity
- Hospital stocking adoption rates
- Real-world comparative effectiveness vs opioids
Counterarguments
- Large, price-sensitive analgesics market may limit branded pricing and share
- Clinical trials showed placebo separation but may not clearly beat opioids, constraining switching
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent protection, Orange Book listing and long basic patent life support branded exclusivity, but large-market incentives attract challengers.
Erosion risks
- Paragraph IV challenges once listed
- Safety signals limiting broad use
Leading indicators
- Patent listings and challenges
- Adverse event reporting and label changes
Counterarguments
- Analgesics are heavily commoditized; patents may not prevent rapid payer substitution
- Competitors could launch differentiated non-opioid mechanisms
Evidence
We have 34 issued U.S. patents listed in the Orange Book
Shows the listed patent estate around TRIKAFTA/KAFTRIO.
We have 35 issued U.S. patents listed in the Orange Book
Shows the listed patent estate around ALYFTREK.
TRIKAFTA/KAFTRIO ... basic product patent ... 2037; ALYFTREK ... 2039.
Basic patent expirations extend into the late 2030s (before any extensions/secondary patents).
entered into an extended long-term reimbursement agreement with NHS England providing access to KAFTRIO, SYMKEVI and ORKAMBI...
Long-term reimbursement can slow competitor displacement and supports stable coverage.
secured reimbursement agreements for ALYFTREK
Q1 2026 filing cites new ALYFTREK reimbursement wins in multiple ex-U.S. markets.
Showing 5 of 18 sources.
Risks & Indicators
Erosion risks
- Patent challenges / invalidation
- Post-expiry generic entry after late-2030s
- Breakthrough non-modulator modalities (gene therapy, mRNA) reducing modulator demand
- Policy-driven price cuts in single-payer systems
- Re-tendering or renegotiation of national reimbursement terms
- Superior efficacy/safety from a new entrant making switching rational
Leading indicators
- Orange Book litigation / Paragraph IV filings
- Competitor CF genetic therapy clinical milestones
- Net realized pricing trend and payer restriction rates
- Public payer re-opener clauses / renegotiation announcements
- HTA outcomes for future CF competitors
- Share of CF population on Vertex medicines
Research VRTX elsewhere
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the Liquid North Atlantic universe, ranked with a multi-measure value system and quality...
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.